Back to Journals » Patient Preference and Adherence » Volume 9

Development of a patient decision aid for type 2 diabetes mellitus for patients not achieving glycemic control on metformin alone

Authors Shillington AC, Col N, Bailey RA, Jewell MA

Received 10 February 2015

Accepted for publication 13 March 2015

Published 30 April 2015 Volume 2015:9 Pages 609—617

DOI https://doi.org/10.2147/PPA.S82555

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Editor who approved publication: Dr Johnny Chen

Video abstract presented by Alicia C Shillington

Views: 193

Alicia C Shillington,1 Nananda Col,2 Robert A Bailey,3 Mark A Jewell1

1EPI-Q, Inc., Oak Brook, IL, USA; 2Shared Decision-making Resources, Georgetown, ME, USA; 3Janssen Scientific Affairs, LLC, Raritan, NJ, USA

Purpose: To describe the process used to develop an evidence-based patient decision aid (PDA) that facilitates shared decision-making for treatment intensification in inadequately controlled type 2 diabetes mellitus (T2DM) consistent with International Patient Decision Aids Standards.
Methods: A PDA was developed by a multidisciplinary steering committee of clinicians, patient advocate, nurse, certified diabetes educators, and decision scientist, using a systematic development process. The process included defining the PDA scope and purpose, outlining the framework, content creation, and designing for integration into clinical practice. This was accomplished through a review of the literature and publically available educational materials and input from practicing clinicians and patients during development and iteratively refining content based on input. Patients with poorly controlled T2DM on metformin considering additional medication assessed the PDA during a pilot.
Results: Testing identified six preference-sensitive domains important for choosing T2DM treatment: degree of glycemic response, avoiding weight gain, hypoglycemia risk and other adverse events, avoiding injections, convenience of dose administration, blood glucose monitoring, and cost of therapy. Patient feedback guided content revision. Treatment options were offered after presenting medication class risk–benefit information and eliciting patient values, goals, and preferences. The PDA received the highest International Patient Decision Aids Standards global score to date, 88/100, with 100% of criteria fully met for the following dimensions: development process, disclosures, evaluation process, evidence quality, guidance for users, information quality, language/readability, testing, and eliciting patient values.
Conclusion: A PDA was developed to help T2DM patients make decisions regarding medication choice. This approach may be applicable to other chronic conditions.

Keywords: patient decision aid, shared decision-making, type 2 diabetes

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Improving access to shared decision-making for Hispanics/Latinos with inadequately controlled type 2 diabetes mellitus

Davidson JA, Rosales A, Shillington AC, Bailey RA, Kabir C, Umpierrez GE

Patient Preference and Adherence 2015, 9:619-625

Published Date: 30 April 2015

Readers of this article also read:

Serous macular detachment, yellow macular deposits, and prominent middle limiting membrane in multiple myeloma

Dogan B, Erol MK, Toslak D, Coban DT, Bulut M, Cengiz A, Sarı ES

Therapeutics and Clinical Risk Management 2015, 11:683-689

Published Date: 30 April 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010